Regulation FD Disclosure
Show detailsHide details
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
Definium Therapeutics, Inc.
A clinical-stage biopharmaceutical company in New York City developing psychedelic-based medicines for psychiatric and neurological disorders. Founded in 2019 as MindMed, a startup exploring LSD and other psychedelics as therapies, it rebranded to Definium Therapeutics in 2026. Its lead program, DT120, is an orally disintegrating tablet of lysergide (LSD) designed to dissolve on the tongue.
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 8.01 Other Events · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits